ABIVAX: Half-Year Report on the Liquidity Contract at 30 June 2016
06 Juillet 2016 - 7:00PM
Business Wire
Regulatory News:
Regarding the liquidity contract assigned by ABIVAX (Paris:ABVX)
(ISIN code: FR0012333284, ticker: ABVX) to TSAF –
Tradition Securities And Futures – on June 26th, 2015, the
liquidity account held the following amounts on June 30, 2016:
- 52 100 shares
- €129,752.62
As a reminder, the liquidity account held the following amounts
at December 31, 2015:
- 43,446 shares
- €195,505.60
ABIVAX is an innovative biotechnology company in the
discovery and development of anti-viral therapeutics and
immunotherapeutics to treat some of the world’s most
life-threatening infectious diseases, including HIV/AIDS and
chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage
research: ABX464 a novel first-in-class resistance-proof oral small
molecule HIV/AIDS therapy; and, ABX203, an immunotherapy recently
approved in Cuba and in late-stage clinical development in other
countries that could cure chronic Hepatitis B. ABIVAX also is
advancing additional anti-viral compounds and immunotherapeutics
that may enter the clinical stage in the coming 18 months. A
recently updated corporate presentation, which includes a timeline
for the company’s anticipated news flow, is available
at www.abivax.com. Follow us on Twitter @ABIVAX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160706005957/en/
ABIVAXInvestor RelationsRaquel Lizarraga, +33 1 53
83 09 63raquel.lizarraga@abivax.comorPress RelationsALIZE
RPCaroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59
/ + 33 1 44 54 36 64abivax@alizerp.com
Abivax (EU:ABVX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abivax (EU:ABVX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
